TMX group TMXmoney

Helix BioPharma Corp. (HBP)
Exchange: Toronto Stock Exchange
$0.840
May 18, 2013, 7:16 PM EDT
Change: -0.08 (-8.70%)
Volume: 5,500

Day Low
0.840
Day High
0.880
52 Week Low
0.500
52 Week High
1.680
  Real-time Streaming Quotes
  Add to Portfolio
  Create Alert
   Free Annual Reports
News Headlines for Helix BioPharma Corp.
Monday, April 8, 2013
8:13 AM EDTHelix BioPharma Corp. Announces L-DOS47 Scientific Poster to Be Presented at American Association for Cancer Research Annual Meeting in Washington, DC - Marketwired
Thursday, April 4, 2013
4:11 PM EDTHelix Biopharma Corp. Initiates Enrollment for Third Cohort and Expansion of Centres in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 - Marketwired
Monday, March 18, 2013
6:42 PM EDTHelix BioPharma Corp. Announces L-DOS47 Scientific Presentation to Be Made at BIT LifeScience's 5th International Congress of Antibodies - Marketwired
Monday, March 11, 2013
6:31 PM EDTHelix BioPharma Corp. Announces Q2 Fiscal 2013 Results - Marketwired
Thursday, March 7, 2013
5:05 PM ESTHelix BioPharma Corp. Announces Extension of 2009 Warrant Expiry Date - Marketwired
Monday, February 25, 2013
9:32 AM ESTHelix BioPharma Announces Director Resignation - Marketwired
Thursday, February 21, 2013
2:10 PM ESTHelix BioPharma Corp. Announces Extension of 2009 Warrant Expiry Date - Marketwired
2:05 PM ESTHelix BioPharma Announces Appointment of Director - Marketwired
Sunday, February 10, 2013
11:06 AM ESTHelix BioPharma Announces Director Resignation - Marketwired
Friday, January 25, 2013
1:00 PM ESTHelix Announces Completion of the Sale of Its Rivex Pharma Division to Pharmascience - Marketwired
Thursday, January 24, 2013
6:13 PM ESTHelix Announces Shareholder Approval for the Sale of Its Rivex Pharma Division to Pharmascience and Other Results of Its Annual General and Special Meeting - Marketwired
Thursday, December 20, 2012
10:10 PM ESTHelix BioPharma Announces Appointment of Director - Marketwired
1:39 PM ESTClinical Update: Helix BioPharma Corp. Completes Enrollment in First Cohort and Initiates Second Cohort in Polish Phase I/II Clinical Study of Its Lung Cancer Drug Candidate L-DOS47 - Marketwired
Monday, December 17, 2012
10:36 AM ESTHelix BioPharma Announces Director Resignations - Marketwired
Friday, December 14, 2012
5:01 PM ESTHelix BioPharma and Merck Terminate Material Transfer and License Option Agreement for Topical Interferon Alpha-2b Development Program - Marketwired
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. View delay times for all exchanges.
Market Data powered by QuoteMedia. See the QuoteMedia and TMX Group Terms of Use.